STOCK TITAN

[8-K] Wellgistics Health, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Wellgistics Health, Inc. filed a Form 8-K under Item 7.01 (Regulation FD) to furnish a press release dated October 13, 2025 as Exhibit 99.1.

The company states the furnished information is not deemed “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference. The press release contains forward-looking statements, and readers are directed to risk disclosures in the company’s SEC filings, including its Form S-1 declared effective on September 25, 2025.

Wellgistics Health, Inc. ha presentato un Form 8-K sotto Item 7.01 (Regulation FD) per fornire un comunicato stampa datato 13 ottobre 2025 come Exhibit 99.1.

La società afferma che le informazioni fornite non sono considerate “depositate” ai fini della Sezione 18 della Exchange Act e non sono incorporate per riferimento. Il comunicato contiene dichiarazioni previsionali e si invita i lettori a consultare le informazioni sui rischi nei filing SEC della società, inclusa la sua Form S-1 dichiarata efficace il 25 settembre 2025.

Wellgistics Health, Inc. presentó un Formulario 8-K bajo Item 7.01 (Regulation FD) para adjuntar un comunicado de prensa con fecha 13 de octubre de 2025 como Exhibit 99.1.

La empresa indica que la información adjunta no se considera “presentada” a efectos de la Sección 18 de la Exchange Act y no está incorporada por referencia. El comunicado contiene declaraciones prospectivas, y se indica a los lectores que consulten las divulgaciones de riesgos en los archivos de la SEC de la empresa, incluida su Form S-1 declarada efectiva el 25 de septiembre de 2025.

Wellgistics Health, Inc.Item 7.01 (Regulation FD)에 따라 Exhibit 99.1로 2025년 10월 13일자 보도자료를 제공하는 Form 8-K를 제출했습니다.

회사는 제공된 정보가 증권거래법 제18조의 목적상 “filed”로 간주되지 않는다고 밝히며 참조에 의해 포함되지 않는다고 명시합니다. 보도자료에는 전망 진술이 포함되어 있으며 독자들에게 회사의 SEC 서류에 있는 위험 공시를 참조하라고 안내합니다. 여기에는 Form S-12025년 9월 25일에 효력이 발생한 것이 포함됩니다.

Wellgistics Health, Inc. a déposé un formulaire 8-K sous l’Article 7.01 (Regulation FD) pour fournir un communiqué de presse daté du 13 octobre 2025 en tant que Exhibit 99.1.

La société indique que les informations fournies ne sont pas considérées comme “fournies” aux fins de l’article 18 de la Exchange Act et ne sont pas incorporées par référence. Le communiqué contient des déclarations prospectives, et les lecteurs sont dirigés vers les divulgations de risques dans les dépôts SEC de la société, y compris son Form S-1 déclaré effectif le 25 septembre 2025.

Wellgistics Health, Inc. hat eine Form 8-K unter Item 7.01 (Regulation FD) eingereicht, um eine am 13. Oktober 2025 datierte Pressemitteilung als Exhibit 99.1 bereitzustellen.

Das Unternehmen erklärt, dass die bereitgestellten Informationen nicht als „eingereicht“ gemäß Abschnitt 18 des Exchange Act gelten und nicht durch Bezugnahme einbezogen sind. Die Pressemitteilung enthält zukunftsgerichtete Aussagen, und die Leser werden auf Risikohinweise in den SEC-Unterlagen des Unternehmens hingewiesen, einschließlich seines Form S-1, das am 25. September 2025 wirksam wurde.

Wellgistics Health, Inc. قدمت نموذج 8-K بموجب البند 7.01 (Regulation FD) لتزويد بيان صحفي مؤرخ بتاريخ 13 أكتوبر 2025 كـ Exhibit 99.1.

وتقول الشركة إن المعلومات المرفقة لا تعتبر “مقدمة” لأغراض البند 18 من قانون التبادل ولا تُدرج بالإشارة كمرجع. يحتوي البيان الصحفي على عبارات مستقبلية، ويُوجّه القراء إلى الإيضاحات المتعلقة بالمخاطر في تسجيلات الشركة لدى هيئة الأوراق المالية، بما في ذلك Form S-1 الذي صدر تفعيله في 25 سبتمبر 2025.

Wellgistics Health, Inc. 已提交一份Form 8-K,依据Item 7.01 (Regulation FD),以提供日期为2025年10月13日的新闻稿,作为Exhibit 99.1

公司表示所提供的信息并不被视为就第18条之证券交易法的“提交(filed)”而具法律效力,且不通过引用被并入。新闻稿包含前瞻性陈述,读者应参阅公司在SEC备案中的风险披露,包括其在Form S-1,于2025年9月25日生效。

Positive
  • None.
Negative
  • None.

Wellgistics Health, Inc. ha presentato un Form 8-K sotto Item 7.01 (Regulation FD) per fornire un comunicato stampa datato 13 ottobre 2025 come Exhibit 99.1.

La società afferma che le informazioni fornite non sono considerate “depositate” ai fini della Sezione 18 della Exchange Act e non sono incorporate per riferimento. Il comunicato contiene dichiarazioni previsionali e si invita i lettori a consultare le informazioni sui rischi nei filing SEC della società, inclusa la sua Form S-1 dichiarata efficace il 25 settembre 2025.

Wellgistics Health, Inc. presentó un Formulario 8-K bajo Item 7.01 (Regulation FD) para adjuntar un comunicado de prensa con fecha 13 de octubre de 2025 como Exhibit 99.1.

La empresa indica que la información adjunta no se considera “presentada” a efectos de la Sección 18 de la Exchange Act y no está incorporada por referencia. El comunicado contiene declaraciones prospectivas, y se indica a los lectores que consulten las divulgaciones de riesgos en los archivos de la SEC de la empresa, incluida su Form S-1 declarada efectiva el 25 de septiembre de 2025.

Wellgistics Health, Inc.Item 7.01 (Regulation FD)에 따라 Exhibit 99.1로 2025년 10월 13일자 보도자료를 제공하는 Form 8-K를 제출했습니다.

회사는 제공된 정보가 증권거래법 제18조의 목적상 “filed”로 간주되지 않는다고 밝히며 참조에 의해 포함되지 않는다고 명시합니다. 보도자료에는 전망 진술이 포함되어 있으며 독자들에게 회사의 SEC 서류에 있는 위험 공시를 참조하라고 안내합니다. 여기에는 Form S-12025년 9월 25일에 효력이 발생한 것이 포함됩니다.

Wellgistics Health, Inc. a déposé un formulaire 8-K sous l’Article 7.01 (Regulation FD) pour fournir un communiqué de presse daté du 13 octobre 2025 en tant que Exhibit 99.1.

La société indique que les informations fournies ne sont pas considérées comme “fournies” aux fins de l’article 18 de la Exchange Act et ne sont pas incorporées par référence. Le communiqué contient des déclarations prospectives, et les lecteurs sont dirigés vers les divulgations de risques dans les dépôts SEC de la société, y compris son Form S-1 déclaré effectif le 25 septembre 2025.

Wellgistics Health, Inc. hat eine Form 8-K unter Item 7.01 (Regulation FD) eingereicht, um eine am 13. Oktober 2025 datierte Pressemitteilung als Exhibit 99.1 bereitzustellen.

Das Unternehmen erklärt, dass die bereitgestellten Informationen nicht als „eingereicht“ gemäß Abschnitt 18 des Exchange Act gelten und nicht durch Bezugnahme einbezogen sind. Die Pressemitteilung enthält zukunftsgerichtete Aussagen, und die Leser werden auf Risikohinweise in den SEC-Unterlagen des Unternehmens hingewiesen, einschließlich seines Form S-1, das am 25. September 2025 wirksam wurde.

false 0002030763 0002030763 2025-10-13 2025-10-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 13, 2025

 

WELLGISTICS HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-42530   93-3264234

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

3000 Bayport Drive

Suite 950

Tampa, FL 33607

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: (844) 203-6092

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
         
Common Stock, $0.0001 par value per share   WGRX   The Nasdaq Capital Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 
 

 

Item 7.01 Regulation FD Disclosure.

 

On October 13, 2025, Wellgistics Health, Inc. (the “Registrant”) issued a press release, a copy of which is furnished as Exhibit 99.1 hereto.

 

The information in this Item 7.01, including Exhibits 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filings. This Report will not be deemed an admission as to the materiality of any information of the information contained in this Item 7.01, including Exhibits 99.1.

 

The press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. With the exception of historical matters, the matters discussed in the press releases include forward-looking statements within the meaning of applicable securities laws. Such forward-looking statements include, among others, statements regarding the Company’s projects, potential financial performance, and growth opportunities. The words “believes,” “expects,” “intends,” “plans,” “anticipates,” “hopes,” “likely,” “will,” and similar expressions are intended to identify certain of these forward-looking statements. These statements are based on the Company’s expectations and involve risks, uncertainties and other important factors that could cause the actual results performance or achievements of the Company (or entities in which the Company has interests), or industry results, to differ materially from future results, performance or achievements expressed or implied by such forward-looking statements. Certain factors that could cause the Company’s actual future results to differ materially from those discussed are noted in connection with such statements, but other unanticipated factors could arise. Certain risks regarding the Company’s forward-looking statements are discussed in the Company’s filings with the Securities and Exchange Commission (“SEC”), including an extensive discussion of these risks in the Company’s Registration Statement on Form S-1, declared effective by the SEC on September 25, 2025. Readers are cautioned not to place undue reliance on these forward-looking statements which reflect management’s view only as of the date of this Form 8-K. The Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, conditions or circumstances.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibits are filed as part of, or incorporated by reference into, this Report.

 

Exhibit No.  Description
99.1  Press Release Dated October 13, 2025
104*  Cover Page Interactive Data File (formatted as Inline XBRL)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: October 17, 2025 WELLGISTICS HEALTH, INC.
     
  By: /s/ Prashant Patel
    Prashant Patel, President

 

 

 

Wellgistics Health Inc.

NASDAQ:WGRX

WGRX Rankings

WGRX Latest News

WGRX Latest SEC Filings

WGRX Stock Data

46.75M
33.31M
60.61%
0.77%
0.97%
Pharmaceutical Retailers
Wholesale-drugs, Proprietaries & Druggists' Sundries
Link
United States
TAMPA